SCHEMBL6324685

SCHEMBL6324685

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)C(Cc1ccc(-c2ccccc2)cc1)NC

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
MME P08473 10/20 0.45
ACE2 Q9BYF1 9/20 0.45
ACE P12821 8/20 0.45
CPA1 P15085 8/20 0.45
MMP9 P14780 2/20 0.44
MMP8 P22894 2/20 0.44
MMP2 P08253 1/20 0.44
MMP14 P50281 1/20 0.42
MMP1 P03956 1/20 0.42
FCER2 P06734 1/20 0.42
MMP12 P39900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319028 1.00 ALDH1A1 (0.49) ALDH1A1MAPTMMEACE2ACE
SCHEMBL6319021 0.88 ALDH1A1 (0.47) ALDH1A1MAPTMMEACE2ACE
SCHEMBL8906561 0.88 MME (0.40) ALDH1A1MAPTMMEACE2ACE
SCHEMBL7063344 0.88 ALDH1A1 (0.49) ALDH1A1MAPTMMEACE2ACE
SCHEMBL4426088 0.87 FCER2 (0.53) MMEACE2ACECPA1MMP9
SCHEMBL4427112 0.87 FCER2 (0.53) MMEACE2ACECPA1MMP9
SCHEMBL6317992 0.87 FCER2 (0.53) MMEACE2ACECPA1MMP9
SCHEMBL8905182 0.87 GHSR (0.45) MMEACE2ACECPA1MMP9
SCHEMBL3272745 0.86 ALDH1A1 (0.48) ALDH1A1MAPTMMEACE2ACE
SCHEMBL8171467 0.86 HDAC3 (0.45) ALDH1A1MAPTMMEACE2ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR ALDH1A1 2542/4885MAPT 4357/4885MME 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.